Assessment of primary prevention patients receiving an ICD – Systematic evaluation of ATP: APPRAISE ATP
Background: The value of antitachycardia pacing (ATP) in the overall cohort of primary prevention patients who receive implantable cardioverter-defibrillators (ICDs) remains uncertain. ATP success reported in prior trials potentially included a large number of patients receiving unnecessary ATP for...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-08-01
|
Series: | Heart Rhythm O2 |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2666501821001203 |
id |
doaj-7586c8a5074a48e19e956726adbbeefd |
---|---|
record_format |
Article |
spelling |
doaj-7586c8a5074a48e19e956726adbbeefd2021-09-03T04:47:45ZengElsevierHeart Rhythm O22666-50182021-08-0124405411Assessment of primary prevention patients receiving an ICD – Systematic evaluation of ATP: APPRAISE ATPClaudio D. Schuger, MD0Kenji Ando, MD1Daniel J. Cantillon, MD2Pier D. Lambiase, MD, PhD3Lluis Mont, MD4Bo Young Joung, MD5Darren Peress, MD6Patrick Yong, MSEE7Nicholas Wold, MS8James P. Daubert, MD9Henry Ford Heart & Vascular Institute, Detroit, Michigan; Address reprint requests and correspondence: Dr Claudio Schuger, Department of Cardiac Electrophysiology, Henry Ford Heart & Vascular Institute, 2799 W Grand Blvd, Detroit, MI 48202.Kokura Memorial Hospital, Kitakyushu, JapanCleveland Clinic, Heart and Vascular Institute, Cardiac Electrophysiology and Pacing, Cleveland, OhioSt. Bartholomew’s Hospital, London, United KingdomDepartment of Cardiology, Hospital Clinic, University of Barcelona, Barcelona, SpainYonsei University Severance Hospital, Seoul, KoreaPima Heart Physicians, PC, Tucson, ArizonaBoston Scientific Corporation, St. Paul, MinnesotaBoston Scientific Corporation, St. Paul, MinnesotaDuke University Medical Center, Durham, North CarolinaBackground: The value of antitachycardia pacing (ATP) in the overall cohort of primary prevention patients who receive implantable cardioverter-defibrillators (ICDs) remains uncertain. ATP success reported in prior trials potentially included a large number of patients receiving unnecessary ATP for arrhythmias that may have self-terminated owing to the prematurity of the intervention. Although some patients derive benefit from initial ATP in terminating rapid ventricular arrhythmias and thereby preventing shocks, there are limited data allowing us to identify those patients a priori. Objective: The purpose of APPRAISE ATP is to understand the role of ATP in primary prevention patients currently indicated for ICD therapy in a large prospective randomized controlled trial with modern programming parameters. Methods: The study is a global, prospective, randomized, multicenter clinical trial conducted at up to 150 sites globally, enrolling approximately 2600 subjects The primary endpoint of the trial is time to first all-cause shock in a 2-arm study with an equivalent study design in which the incidence of all-cause shocks will be compared between primary prevention subjects programmed with shocks only vs subjects programmed to standard therapy (ATP and shock). Results: An Electrogram and Device Interrogation Core Laboratory will review interrogation data to determine primary endpoints that occur in APPRAISE ATP. Their decisions are based on independent physician review of the data from device interrogation. Conclusion: The ultimate purpose of the study is to aid clinicians in the selection of ICD technologies based on hard endpoint evidence across the spectrum of indications for primary prevention implantation.http://www.sciencedirect.com/science/article/pii/S2666501821001203ICDPrimary preventionVT |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Claudio D. Schuger, MD Kenji Ando, MD Daniel J. Cantillon, MD Pier D. Lambiase, MD, PhD Lluis Mont, MD Bo Young Joung, MD Darren Peress, MD Patrick Yong, MSEE Nicholas Wold, MS James P. Daubert, MD |
spellingShingle |
Claudio D. Schuger, MD Kenji Ando, MD Daniel J. Cantillon, MD Pier D. Lambiase, MD, PhD Lluis Mont, MD Bo Young Joung, MD Darren Peress, MD Patrick Yong, MSEE Nicholas Wold, MS James P. Daubert, MD Assessment of primary prevention patients receiving an ICD – Systematic evaluation of ATP: APPRAISE ATP Heart Rhythm O2 ICD Primary prevention VT |
author_facet |
Claudio D. Schuger, MD Kenji Ando, MD Daniel J. Cantillon, MD Pier D. Lambiase, MD, PhD Lluis Mont, MD Bo Young Joung, MD Darren Peress, MD Patrick Yong, MSEE Nicholas Wold, MS James P. Daubert, MD |
author_sort |
Claudio D. Schuger, MD |
title |
Assessment of primary prevention patients receiving an ICD – Systematic evaluation of ATP: APPRAISE ATP |
title_short |
Assessment of primary prevention patients receiving an ICD – Systematic evaluation of ATP: APPRAISE ATP |
title_full |
Assessment of primary prevention patients receiving an ICD – Systematic evaluation of ATP: APPRAISE ATP |
title_fullStr |
Assessment of primary prevention patients receiving an ICD – Systematic evaluation of ATP: APPRAISE ATP |
title_full_unstemmed |
Assessment of primary prevention patients receiving an ICD – Systematic evaluation of ATP: APPRAISE ATP |
title_sort |
assessment of primary prevention patients receiving an icd – systematic evaluation of atp: appraise atp |
publisher |
Elsevier |
series |
Heart Rhythm O2 |
issn |
2666-5018 |
publishDate |
2021-08-01 |
description |
Background: The value of antitachycardia pacing (ATP) in the overall cohort of primary prevention patients who receive implantable cardioverter-defibrillators (ICDs) remains uncertain. ATP success reported in prior trials potentially included a large number of patients receiving unnecessary ATP for arrhythmias that may have self-terminated owing to the prematurity of the intervention. Although some patients derive benefit from initial ATP in terminating rapid ventricular arrhythmias and thereby preventing shocks, there are limited data allowing us to identify those patients a priori. Objective: The purpose of APPRAISE ATP is to understand the role of ATP in primary prevention patients currently indicated for ICD therapy in a large prospective randomized controlled trial with modern programming parameters. Methods: The study is a global, prospective, randomized, multicenter clinical trial conducted at up to 150 sites globally, enrolling approximately 2600 subjects The primary endpoint of the trial is time to first all-cause shock in a 2-arm study with an equivalent study design in which the incidence of all-cause shocks will be compared between primary prevention subjects programmed with shocks only vs subjects programmed to standard therapy (ATP and shock). Results: An Electrogram and Device Interrogation Core Laboratory will review interrogation data to determine primary endpoints that occur in APPRAISE ATP. Their decisions are based on independent physician review of the data from device interrogation. Conclusion: The ultimate purpose of the study is to aid clinicians in the selection of ICD technologies based on hard endpoint evidence across the spectrum of indications for primary prevention implantation. |
topic |
ICD Primary prevention VT |
url |
http://www.sciencedirect.com/science/article/pii/S2666501821001203 |
work_keys_str_mv |
AT claudiodschugermd assessmentofprimarypreventionpatientsreceivinganicdsystematicevaluationofatpappraiseatp AT kenjiandomd assessmentofprimarypreventionpatientsreceivinganicdsystematicevaluationofatpappraiseatp AT danieljcantillonmd assessmentofprimarypreventionpatientsreceivinganicdsystematicevaluationofatpappraiseatp AT pierdlambiasemdphd assessmentofprimarypreventionpatientsreceivinganicdsystematicevaluationofatpappraiseatp AT lluismontmd assessmentofprimarypreventionpatientsreceivinganicdsystematicevaluationofatpappraiseatp AT boyoungjoungmd assessmentofprimarypreventionpatientsreceivinganicdsystematicevaluationofatpappraiseatp AT darrenperessmd assessmentofprimarypreventionpatientsreceivinganicdsystematicevaluationofatpappraiseatp AT patrickyongmsee assessmentofprimarypreventionpatientsreceivinganicdsystematicevaluationofatpappraiseatp AT nicholaswoldms assessmentofprimarypreventionpatientsreceivinganicdsystematicevaluationofatpappraiseatp AT jamespdaubertmd assessmentofprimarypreventionpatientsreceivinganicdsystematicevaluationofatpappraiseatp |
_version_ |
1717817848376590336 |